Lanova Medicines Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 16, 2027The maintenance fee for ANTI-CCR8 Monoclonal Antibodies and Uses Thereof (US 11,873,342) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,882,853 | Tyrosine kinase inhibitor and application thereof In force · USPTO record | In force | USPTO record | |
| US 11,059,887 | Anti-Claudin 18.2 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,098,118 | Anti-Claudin 18.2 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,018,076 | Anti-Claudin 18.2 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,554,177 | Antibody-Drug Conjugates Targeting Human Claudin 18.2 In force · High confidence | In force | High confidence | |
| US 12,324,936 | Methods of Treating Cancer by Administering an Antibody-Drug Conjugate Targeting Human Claudin 18.2 In force · High confidence | In force | High confidence | |
| US 11,873,342 | ANTI-CCR8 Monoclonal Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,692,318 | ANTI-4-1BB Nanobodies In force · Medium confidence | In force | Medium confidence | |
| US 12,570,742 | ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOF In force · High confidence | In force | High confidence | |
| US 12,291,537 | Compounds, Compositions and Methods In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending